CN1212119C - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN1212119C
CN1212119C CNB01820032XA CN01820032A CN1212119C CN 1212119 C CN1212119 C CN 1212119C CN B01820032X A CNB01820032X A CN B01820032XA CN 01820032 A CN01820032 A CN 01820032A CN 1212119 C CN1212119 C CN 1212119C
Authority
CN
China
Prior art keywords
formula
corticosteroid
chemical compound
free
useful salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB01820032XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1477963A (zh
Inventor
B·屈埃努
R·A·费尔赫斯特
N·劳瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1477963A publication Critical patent/CN1477963A/zh
Application granted granted Critical
Publication of CN1212119C publication Critical patent/CN1212119C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CNB01820032XA 2000-12-04 2001-12-03 有机化合物 Expired - Lifetime CN1212119C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0029562.6 2000-12-04
GBGB0029562.6A GB0029562D0 (en) 2000-12-04 2000-12-04 Organic compounds

Publications (2)

Publication Number Publication Date
CN1477963A CN1477963A (zh) 2004-02-25
CN1212119C true CN1212119C (zh) 2005-07-27

Family

ID=9904414

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB01820032XA Expired - Lifetime CN1212119C (zh) 2000-12-04 2001-12-03 有机化合物

Country Status (27)

Country Link
US (5) US6800643B2 (https=)
EP (2) EP1772142A3 (https=)
JP (2) JP2004514739A (https=)
KR (1) KR100523541B1 (https=)
CN (1) CN1212119C (https=)
AT (1) ATE361077T1 (https=)
AU (2) AU2002217082B2 (https=)
BR (1) BRPI0115910B8 (https=)
CA (1) CA2427282C (https=)
CY (1) CY1106727T1 (https=)
CZ (1) CZ304294B6 (https=)
DE (1) DE60128258T2 (https=)
DK (1) DK1341542T3 (https=)
EC (1) ECSP034620A (https=)
ES (1) ES2284732T3 (https=)
GB (1) GB0029562D0 (https=)
HU (1) HU229552B1 (https=)
IL (2) IL155709A0 (https=)
MX (1) MXPA03004976A (https=)
NO (1) NO325692B1 (https=)
NZ (1) NZ525731A (https=)
PL (1) PL204002B1 (https=)
PT (1) PT1341542E (https=)
RU (1) RU2292890C2 (https=)
SK (1) SK287331B6 (https=)
WO (1) WO2002045703A2 (https=)
ZA (1) ZA200303399B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831445A (zh) * 2016-11-22 2017-06-13 斯芬克司药物研发（天津）股份有限公司 一种茚基胺化合物的制备方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US20040146509A1 (en) * 2002-07-25 2004-07-29 Zhihe Li Methods for improvement of lung function using TGF-beta inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
KR100666220B1 (ko) * 2005-01-31 2007-01-09 영남대학교 산학협력단 구내염 치료용 분사제 조성물
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2009520823A (ja) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー 薬物動態学的プロフィールの向上を有するコルチコステロイドを送達するための方法およびシステム
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
MY150468A (en) * 2006-06-30 2014-01-30 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
KR100940388B1 (ko) * 2009-07-01 2010-02-02 유병덕 스크류탈수기 및 이를 포함하는 유기성폐기물 건조장치
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
RU2568882C2 (ru) * 2010-07-16 2015-11-20 Сипла Лимитед Фармацевтические композиции
RU2642624C2 (ru) * 2010-10-12 2018-01-25 Сипла Лимитед Фармацевтическая композиция
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN102247380A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布地奈德与茚达特罗为活性成分的复方制剂
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
ITUB20153978A1 (it) * 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN110229078A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 一种茚达特罗起始原料开环杂质的制备
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希（南京）药物研发有限公司 一种茚达特罗杂质的制备方法
KR102748506B1 (ko) 2024-07-02 2024-12-31 주식회사 지티피에스 자동 청소기능을 갖는 건조장치

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
WO1993018007A1 (fr) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
MY107767A (en) * 1992-04-10 1996-06-15 Merck Frosst Canada Inc Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9501286D0 (en) * 1995-01-24 1995-03-15 Ciba Geigy Ag Pharmaceutical compositions and preparations thereof
DE69630639T2 (de) * 1995-08-16 2004-09-16 Huntington Medical Research Institutes, Pasadena Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
TW375604B (en) 1996-02-19 1999-12-01 Kissei Pharmaceutical 3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives
GB9610122D0 (en) * 1996-05-15 1996-07-24 Reckitt & Colmann Prod Ltd Organic compositions
US6172099B1 (en) * 1997-07-03 2001-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Tricyclic compounds having saturated rings and medicinal compositions containing the same
DE29923847U1 (de) * 1998-05-27 2001-04-12 Euroceltique S.A., Luxemburg/Luxembourg Präparate zur Anwendung von entzündungshemmenden, insbesondere antiseptischen Wirkstoffen und/oder die Wundheilung fördernden Wirkstoffen in den unteren Atemwegen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US6664235B1 (en) * 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831445A (zh) * 2016-11-22 2017-06-13 斯芬克司药物研发（天津）股份有限公司 一种茚基胺化合物的制备方法

Also Published As

Publication number Publication date
CN1477963A (zh) 2004-02-25
PL204002B1 (pl) 2009-12-31
WO2002045703A2 (en) 2002-06-13
CZ304294B6 (cs) 2014-02-19
ECSP034620A (es) 2003-06-25
KR20030048065A (ko) 2003-06-18
IL155709A (en) 2008-11-26
GB0029562D0 (en) 2001-01-17
HU229552B1 (en) 2014-01-28
CY1106727T1 (el) 2012-05-23
PT1341542E (pt) 2007-08-01
JP2004514739A (ja) 2004-05-20
RU2003119549A (ru) 2005-02-10
CA2427282C (en) 2010-10-19
SK287331B6 (sk) 2010-07-07
ZA200303399B (en) 2004-04-23
NO20032510D0 (no) 2003-06-03
US20040038951A1 (en) 2004-02-26
KR100523541B1 (ko) 2005-10-25
EP1341542A2 (en) 2003-09-10
BRPI0115910B8 (pt) 2021-05-25
EP1772142A3 (en) 2011-09-14
IL155709A0 (en) 2003-11-23
HUP0302571A3 (en) 2005-05-30
HUP0302571A2 (hu) 2003-11-28
EP1772142A2 (en) 2007-04-11
DK1341542T3 (da) 2007-09-03
RU2292890C2 (ru) 2007-02-10
US20060052352A1 (en) 2006-03-09
DE60128258T2 (de) 2007-12-27
US6800643B2 (en) 2004-10-05
CA2427282A1 (en) 2002-06-13
AU2002217082B2 (en) 2005-04-07
ES2284732T3 (es) 2007-11-16
BRPI0115910B1 (pt) 2019-12-31
NO20032510L (no) 2003-06-03
PL362443A1 (en) 2004-11-02
BR0115910A (pt) 2004-01-20
US20050009795A1 (en) 2005-01-13
SK6502003A3 (en) 2003-12-02
MXPA03004976A (es) 2003-09-05
CZ20031537A3 (cs) 2003-10-15
ATE361077T1 (de) 2007-05-15
EP1341542B1 (en) 2007-05-02
JP2007302684A (ja) 2007-11-22
NO325692B1 (no) 2008-07-07
US7622484B2 (en) 2009-11-24
DE60128258D1 (de) 2007-06-14
HK1059564A1 (en) 2004-07-09
WO2002045703A3 (en) 2003-03-13
NZ525731A (en) 2004-11-26
AU1708202A (en) 2002-06-18
US20100068288A1 (en) 2010-03-18
US7008951B2 (en) 2006-03-07
US20120108555A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
CN1212119C (zh) 有机化合物
CN1213047C (zh) 酪氨酸蛋白激酶syk的嘌呤衍生物抑制剂
CN1145478C (zh) 药用气溶胶制剂
CN1917875A (zh) 治疗呼吸疾病的苯并噻唑－2－酮β2肾上腺素受体激动剂与皮质类固醇的组合
CN1272334C (zh) 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
CN1275962C (zh) 可作为药物的抗胆碱能制剂及其制备方法
CN1231467C (zh) 伤害感受蛋白受体orl－1的高亲合性配体，包含它们的药物组合物以及它们的用途
CN1156451C (zh) β2-肾上腺受体激动剂
CN1324025C (zh) 作为ccr5调节剂的托烷衍生物
CN1816549A (zh) 磷脂酰肌醇3－激酶抑制剂
CN1291986C (zh) 抗胆碱能剂,其制备方法及其作为药物的用途
CN1713914A (zh) 用于治疗慢性阻塞性肺病的新药物
CN1659147A (zh) 哒嗪衍生物
CN1541097A (zh) 2-氨基-4,5-三取代噻唑基衍生物
CN101056634A (zh) 奎宁环衍生物及它们作为毒蕈碱m3受体拮抗剂的用途
CN1269722A (zh) 调节对皮质类固醇反应的方法及组合物
CN1680425A (zh) 作为抗炎剂的17β－硫代羧酸酯17α－芳基羰氧基雄甾烷衍生物
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CN1826339A (zh) 2－酰氨基－4－苯基噻唑衍生物,其制备方法及其在治疗学上的应用
CN1642535A (zh) 使用截短侧耳素衍生物治疗肺结核
CN1382141A (zh) 1,8－二氮杂萘衍生物
CN1166361C (zh) 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂
CN101039937A (zh) 在呼吸系统疾病的治疗中用作β模拟剂的杂芳基化合物
CN1585641A (zh) 亚肼基－丙二腈化合物
CN1322130A (zh) 抑制3型3α－羟基类固醇脱氢酶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050727